M MtoZ Biolabs
Home > Support > Resources > Comparison of Mass Spectrometry MRM With iTRAQ/TMT Quantification

Comparison of Mass Spectrometry MRM With iTRAQ/TMT Quantification

By Jacob Hall · Published: November 16, 2026

Choose MRM when a closed peptide list needs scheduled precursor-to-product transitions for relative confirmation or absolute amount with standards; choose iTRAQ or TMT when many proteins must be compared as relative ratios inside one isobaric plex after amine labeling and pooling (Lange et al. 2008; Thompson et al. 2003). MRM is targeted acquisition on typically a triple quadrupole; iTRAQ/TMT are multiplex labeling chemistries usually read by discovery-style LC-MS/MS reporters. They answer different claims and do not replace each other: MRM does not survey an open proteome, and ordinary TMT or iTRAQ reporters are not absolute concentration. Prefer discovery LFQ or DIA first when candidates are still unknown.

Researchers who already have defined samples, comparison groups, or a specific project objective can also review the MtoZ Biolabs SRM-MRM Quantitative Proteomics Services and TMT Quantitative Proteomics Analysis Service for project-specific feasibility and assay planning.

Comparison at a Glance: Different Method Layers

Dimension

MRM (also called SRM)

iTRAQ / TMT

Method layer

Targeted acquisition schedule

Isobaric labeling chemistry

What is measured

Predefined peptide transitions

Reporter ions from pooled labeled channels

Inventory

Closed peptide list required

Open discovery inside one plex is common

Enrollment

Independent injections of the panel

Must freeze samples before pooling

Default claim

Relative confirmation; absolute only with SIS

Relative ratios inside the plex

Typical strength

Selectivity for nominated targets

Same-run multi-sample multiplex discovery

Typical limit

Does not find unscheduled proteins

Ratio compression; no late enrollment

Side-by-side comparison of MRM closed-list transitions versus iTRAQ or TMT isobaric labeling and reporter-ratio quantification

Figure 1. MRM and iTRAQ/TMT are not interchangeable quantification recipes: one is targeted acquisition; the other is multiplex isobaric labeling.

Ranking “sensitivity” without stating panel status, plex closure, and relative-versus-absolute claim misleads method selection.

How to Choose: Selection Criteria

Selection question

Prefer MRM

Prefer iTRAQ / TMT

Prefer another route

Are proteotypic peptides already nominated?

Yes

Not required for discovery inside the plex

No → LFQ or DIA first

Must many conditions share one MS run?

Not the main reason

Yes, if amine chemistry and loads match

Enrollment open → LFQ/DIA

Is absolute peptide amount required?

Yes, with SIS and calibration

No by default

AQUA/PRM designs may fit better

Is the matrix complex and the panel still refining?

Consider PRM instead or after MRM

Discovery plex may still help nominate

Unit-resolution interference dominates

Is sample input too scarce for tags and QC?

Possible if panel is tiny

Often blocked

Unlabeled discovery

Selection criteria comparing MRM and iTRAQ or TMT across panel status, enrollment freeze, and relative versus absolute claims

Figure 2. Selection follows claim and design gates: closed-list targeting versus frozen multiplex labeling.

iTRAQ and TMT share the isobaric-label family. Kit chemistry and channel count differ, but both require matched amine-compatible prep and a frozen map. MRM shares the closed-list idea with PRM; PRM stores full high-resolution MS2 and often fits complex digests during panel refinement (Peterson et al. 2012).

For TMT principle and workflow, see TMT Protein Quantification and Tandem Mass Tag Quantitative Proteomics. For MRM principle, see Principle of Multiple Reaction Monitoring and SRM Mass Spectrometry. For PRM versus MRM, see PRM vs MRM: Comparative Analysis in Quantitative Proteomics. For validation planning after discovery, see How to Plan a Targeted Proteomics Validation Study.

Judgment Criteria: When Each Route Fits

Study need

MRM often fits

iTRAQ / TMT often fit

Reassess

Claim

Confirm named peptides; optional absolute with SIS

Relative multi-arm discovery in one plex

Diagnostic cutoff without validated framework

Scale

Short to moderate closed panel

Broad relative proteome inside kit capacity

Panel unknown and plex cannot freeze

Chemistry

No isobaric labeling required

Amine cleanup and equal load feasible

Residual amines or scarce input

Sequence in a program

After LFQ/DIA/TMT nominates candidates

Early multi-condition screen when plex fits

Treating MRM as open discovery

Prefer a common research sequence when needed: unlabeled or isobaric discovery → close a shortlist → MRM or PRM confirmation → add SIS only if amount units are required. That sequence is a project plan, not a rule every study must follow.

Decision flow from open discovery to iTRAQ or TMT multiplex screens or MRM closed-panel confirmation and optional SIS absolute assays

Figure 3. Choose MRM for closed-list targeting and iTRAQ/TMT for frozen multiplex relative discovery; keep LFQ or DIA when candidates are still unknown.

For labeling versus unlabeled discovery, see Comparing LFQ and Isobaric Labeling Strategies in Proteomics Quantification. For absolute designs on MRM or PRM, see Absolute Quantification in Targeted Proteomics and AQUA Proteomics.

Limits and Application Boundaries

MRM does not measure peptides absent from the transition list. iTRAQ/TMT do not accept late samples after pooling and do not create absolute concentration from reporters alone. Ratio compression can shrink TMT or iTRAQ fold changes; unit-resolution MRM can suffer transition interference. Pathway enrichment from either route reflects the quantified background of that experiment, not proven pathway activity.

Typical paired applications:

  • Multi-arm drug or genotype screens by TMT or iTRAQ, then MRM confirmation of a shortlist.
  • Biomarker-candidate validation by MRM after discovery nominates proteotypic peptides.
  • Pharmacodynamic closed panels by MRM when enrollment stays open across many independent injections.
  • Absolute peptide amount by MRM plus SIS when calibrators and spike timing are planned.

Diagnostic cutoffs and companion-diagnostic claims sit outside ordinary research MRM or isobaric reporting unless a separately validated assay framework is in place.

Once panel status, plex feasibility, and claim type are defined, the project can be scoped as MRM targeting, iTRAQ/TMT multiplex discovery, or a staged combination. Researchers can review the MtoZ Biolabs Targeted Proteomics Service and TMT Quantitative Proteomics Analysis Service for sample evaluation and workflow planning.

Frequently Asked Questions

1. Is MRM simply more accurate than iTRAQ/TMT?

No. Accuracy follows design and QC. MRM is selective for closed targets; iTRAQ/TMT excel at multiplex relative discovery inside a plex.

2. Can iTRAQ/TMT replace MRM for absolute quantification?

Not by reporter ions alone. Absolute amount needs matched standards and calibration, commonly on a targeted platform.

3. Can MRM replace TMT for a 16-sample treatment screen?

Usually not as the sole discovery route. MRM needs a closed list; TMT can compare many proteins across channels in one mix when chemistry holds.

4. Should I choose PRM instead of MRM in this comparison?

Choose PRM when accurate-mass fragment review helps in complex digests or the panel is still refining. Choose MRM when transitions are locked and high multiplex on a triple quadrupole is required.

5. What if candidates are still unknown?

Start with LFQ, DIA, or an isobaric discovery plex. Move to MRM only after peptides are nominated.

Reference

  1. V. Lange, P. Picotti, B. Domon, R. Aebersold (2008). Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol., 4, 222. https://doi.org/10.1038/msb.2008.61
  2. A. Thompson, J. Schafer, K. Kuhn, et al. (2003). Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal. Chem., 75, 1895-1904. https://doi.org/10.1021/ac0262560
  3. A.C. Peterson, J.D. Russell, D.J. Bailey, M.S. Westphall, J.J. Coon (2012). Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Mol. Cell. Proteomics, 11, 1475-1488. https://doi.org/10.1074/mcp.O112.020131

Support Documents

Quantitative Proteomics: Label-Based and Label-Free Strategies

Compare label-based and label-free quantitative proteomics strategies and explore their applications to help identify a suitable approach for your research.

Protein Quantification for Deeper Discovery

Gain a clearer understanding of protein quantification approaches and their applications in studying protein abundance changes by downloading our detailed brochure.

Submit the form below to download the
This checkbox is required
* I agree to receive other communications from MtoZ Biolabs, which may contain technical or marketing information. You can unsubscribe from thlese communications at any time.
SUBMIT
 

How to Order

How to Order
Request a Quote

Request a Project Quote

Please complete the required fields below. We will review your information and respond with a tailored recommendation.

Project inquiry

Fields marked with * are required for quote review.

Secure inquiry · No obligation
Required Information

Your information will be used only to respond to your inquiry.

Submit Inquiry